Consensus is for FY25 revenue $1.37B. Maintains guidance for U.S. Thrombectomy growth of 20% to 21% compared to 2024 levels and for both gross margin and operating margin for FY25.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Buy Rating on Penumbra: Capitalizing on Positive STORM-PE Trial Results and Market Misunderstanding
- Penumbra Inc. (PEN) Q3 Earnings Cheat Sheet
- William Blair healthcare analysts hold analyst/industry conference call
- Penumbra Inc. Launches i-RISE Study to Enhance Stroke Treatment Insights
- Penumbra Inc.’s STRIKE-PE Study: A Game Changer for Pulmonary Embolism Treatment?